lonafarnib has been researched along with saracatinib in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (saracatinib) | Trials (saracatinib) | Recent Studies (post-2010) (saracatinib) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 194 | 25 | 157 |
| Protein | Taxonomy | lonafarnib (IC50) | saracatinib (IC50) |
|---|---|---|---|
| Chain A, Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.0027 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.03 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 1.9615 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.004 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.0038 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.2 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.0093 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 10 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 10 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0027 | |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | 0.84 | |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | 5.209 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer, S; Pillaiyar, T | 1 |
1 review(s) available for lonafarnib and saracatinib
| Article | Year |
|---|---|
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |